Pacira Pharmaceuticals Incorporated
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$67.3M
Doctors Paid
42,718
Transactions
99,831
2024 Total
$5.4M
Payment Breakdown by Category
Research$27.0M (40.1%)
Consulting$11.6M (17.2%)
Travel$3.9M (5.8%)
Food & Beverage$3.1M (4.5%)
Royalty/License$1,600 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $27.0M | 1,516 | 40.1% |
| Consulting Fee | $11.6M | 3,562 | 17.2% |
| Current or prospective ownership or investment interest | $7.7M | 188 | 11.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $7.4M | 2,366 | 11.0% |
| Travel and Lodging | $3.9M | 14,970 | 5.8% |
| Food and Beverage | $3.1M | 75,602 | 4.5% |
| Honoraria | $3.0M | 995 | 4.5% |
| Grant | $2.1M | 83 | 3.2% |
| Space rental or facility fees (teaching hospital only) | $637,750 | 109 | 0.9% |
| Compensation for serving as faculty or as a speaker for a medical education program | $384,481 | 9 | 0.6% |
| Education | $276,413 | 384 | 0.4% |
| Gift | $270,969 | 19 | 0.4% |
| Long term medical supply or device loan | $36,498 | 26 | 0.1% |
| Royalty or License | $1,600 | 1 | 0.0% |
| Charitable Contribution | $890.00 | 1 | 0.0% |
Payments by Type
General
$40.4M
98,315 transactions
Research
$27.0M
1,516 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF FEMORAL NERVE BLOCK WITH EXPAREL FOR POSTSURGICAL ANALGESIA IN SUBJECTS UNDERGOING TOTAL KNEE ARTHROPLASTY | $3.3M | 0 | 176 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF BRACHIAL PLEXUS BLOCK WITH EXPAREL FOR POSTSURGICAL ANALGESIA IN SUBJECTS UNDERGOING TOTAL SHOULDER ARTHROPLASTY OR ROTATOR CUFF REPAIR | $2.7M | 0 | 141 |
| A MULTICENTER, RANDOMIZED, ACTIVE-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF EXPAREL WHEN ADMINISTERED VIA INFILTRATION INTO THE TRANSVERSUS ABDOMINIS PLANE VERSUS STANDARD OF CARE IN SUBJECTS UNDERGOING ELECTIVE CESAREAN SECTION | $2.2M | 0 | 136 |
| COMPARISON OF BILATERAL TRANSVERSUS ABDOMINIS PLANE BLOCK WITH EXPAREL VERSUS CONTINUOUS EPIDURAL ANALGESIA WITH BUPIVACAINE A RANDOMIZED, CONTROLLED TRIAL | $1.8M | 0 | 32 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF EXPAREL WHEN ADMINISTERED VIA INFILTRATION INTO THE TRANSVERSUS ABDOMINIS PLANE TAP VERSUS BUPIVACAINE ALONE IN SUBJECTS UNDERGOING ELECTIVECESAREANSECTION | $1.5M | 0 | 93 |
| A PHASE 1, RANDOMIZED, DOUBLE-BLIND, THREE-PERIOD, THREE-SEQUENCE CROSSOVER STUDY TO EVALUATE THE BIOEQUIVALENCE OF TWO LOTS OF EXPAREL FROM DIFFERENT MANUFACTURING FACILITIES FOLLOWING ADMINISTRATION VIA LOCAL INFILTRATION TO HEALTHY SUBJECTS | $1.4M | 0 | 8 |
| A PHASE 1, PILOT, OPEN LABEL, DOSE ESCALATION STUDY TO EVALUATE THE PHARMACOKINETICS, PHARMACODYNAMICS AND SAFETY, OF EXPAREL ADMINISTERED AS SCIATIC NERVE BLOCK IN POPLITEAL FOSSA, FOR POSTSURGICAL ANALGESIA IN SUBJECTS UNDERGOING BUNIONECTOMY | $1.2M | 0 | 5 |
| A MULTICENTER, RANDOMIZED, DOUBLE BLIND, CONTROLLED TRIAL COMPARING LOCAL INFILTRATION ANALGESIA WITH EXPAREL TO LOCAL INFILTRATION ANALGESIA WITHOUT EXPAREL TO MANAGE POSTSURGICAL PAIN FOLLOWING TOTAL KNEE ARTHROPLASTY | $1.0M | 1 | 110 |
| A MULTICENTER STUDY TO EVALUATE THE PHARMACOKINETICS AND SAFETY OF EXPAREL FOR POSTSURGICAL ANALGESIA IN PEDIATRIC SUBJECTS AGED 6 TO LESS THAN 17 YEARS. | $964,635 | 0 | 90 |
| A MULTICENTER STUDY TO EVALUATE THE PHARMACOKINETICS AND SAFETY OF EXPAREL FOR POSTSURGICAL ANALGESIA IN PEDIATRIC SUBJECTS AGED 6 TO LESS THAN 17 YEARS (PLAY) | $942,681 | 0 | 27 |
| A PHASE 1, PILOT, OPEN LABEL, STUDY TO EVALUATE THE PHARMACOKINETICS, AND SAFETY, OF EXPAREL ADMINISTERED AS PECTORAL PLANE BLOCK IN WOMEN UNDERGOING BREAST AUGMENTATION SURGERY | $926,288 | 0 | 17 |
| A PHASE 1, RANDOMIZED, DOUBLE BLIND, THREE PERIOD, THREE SEQUENCE CROSSOVER STUDY WITH AN OPTIONAL OPEN-LABEL FOURTH PERIOD TO EVALUATE THE BIOEQUIVALENCE OF UP TO THREE LOTS OF EXPAREL FOLLOWING ADMINISTRATION VIA LOCAL INFILTRATION TO HEALTHY SUBJECTS | $901,186 | 0 | 6 |
| A MULTICENTER, RANDOMIZED, CONTROLLED, PHASE 4, PRAGMATIC STUDY OF MULTIMODAL ANALGESIA USING LOCAL INFILTRATION WITH A SINGLE-DOSE OF EXPAREL VS. USUAL CARE FOR POSTSURGICAL ANALGESIA AFTER POSTERIOR LUMBAR SPINE FUSION SURGERY | $728,439 | 0 | 57 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY OF EXPAREL FOR POSTSURGICAL PAIN MANAGEMENT IN SUBJECTS UNDERGOING OPEN LUMBAR SPINAL FUSION SURGERY | $705,199 | 0 | 185 |
| CHARACTERIZATION OF BIO-PSYCHOSOCIAL PAIN PROFILES IN THE PERIOPERATIVE PERIOD | $571,814 | 0 | 7 |
| PHASE 1, RANDOMIZED, DOUBLE-BLIND, ACTIVE AND PLACEBO CONTROLLED, DOSE ESCALATION STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF EXPAREL? ADMINISTERED VIA A SINGLE INTRATHECAL INJECTION TO HEALTHY VOLUNTEERS | $557,443 | 0 | 8 |
| RETROSPECTIVE ANALYSIS OF PEDIATRIC UTILIZATION OF LOPOSOMAL BUPIVACAINE | $468,605 | 0 | 3 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF BRACHIAL PLEXUS BLOCK WITHEXPAREL FOR POSTSURGICAL ANALGESIA INSUBJECTSUNDERGOING TOTALSHOULDERARTHROPLASTY OR ROTATOR CUFF REPAIR | $325,760 | 0 | 19 |
| PECTORALIS AND SERRATUS MUSCHLE BLOCKS FOR ANALGESIA AFTER MINIMALLY INVASIVE CARDIAC PROCEDURES: A RANDOMIZED CLINICAL TRIAL | $310,025 | 0 | 3 |
| A RANDOMIZED, SINGLE-BLIND, ACTIVE-CONTROLLED, DOSE-RANGING STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY, AND EFFICACY OF LOCAL ADMINISTRATION OF DEPOTXA FOR REDUCED POSTSURGICAL BLEEDING IN SUBJECTS UNDERGOING TOTAL KNEE ARTHROPLASTY | $284,578 | 0 | 17 |
| A Multicenter, Randomized, Double-Blind, Sham-Controlled Study Assessing the Efficacy and Safety of iovera®° system in Subjects with Upper Extremity Spasticity | $278,645 | 0 | 104 |
| A Multicenter, Open-label, Randomized, Bupivacaine-Controlled Study to Evaluate the Pharmacokinetics and Safety of EXPAREL for Postoperative Analgesia in Subjects Aged 0 to Less Than 6 Years Undergoing Cardiac Surgery | $242,319 | 0 | 34 |
| MEASURING SURGICAL RECOVERY AFTER RADICAL CYSTECTOMY | $224,700 | 0 | 4 |
| A PHASE 1, OPEN-LABEL STUDY TO EVALUATE PHARMACOKINETICS AND SAFETY OF LOCAL ADMINISTRATION OF EXPAREL FOR POSTSURGICAL ANALGESIA IN PEDIATRICSUBJECTS12TOLESSTHAN17YEARS OF AGE | $210,510 | 0 | 6 |
| A PHASE 3, RANDOMIZED, DOUBLE BLINDED, ACTIVE CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY & PHARMACOKINETICS OF EXPAREL VS BUPIVACAINE ADMINISTERED AS COMBINED SCIATIC (IN POPLITEAL FOSSA) AND FEMORAL TRIANGLE NERVE BLOCK, FOR POSTSURGICAL ANALGESIA IN SUBJECTS UNDERGOING LOWER EXTREMITY SURGERIES (STRIDE) | $194,204 | 0 | 17 |
| THREE ARM RANDOMIZED CONTROLLED TRIAL - EXPAREL VS. BUPIVACAINE HYDROCHLORIDE VS. PLACEBO FOR TAP BLOCKS DURING OPEN RETROMUSCULAR VENTRAL HERNIA REPAIR | $191,910 | 0 | 9 |
| RETROSPECTIVE REVIEW OF LIPOSOMAL BUPIVACAINE FOR POST-OPERATIVE INCISIONAL PAIN CONTROL IN PEDIATRIC SPINAL DEFORMITY SURGERY | $178,656 | 0 | 4 |
| A PHASE 1, RANDOMIZED, TWO-PERIOD, TWO-SEQUENCE CROSSOVER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF DEPOMLX FOLLOWING SUBCUTANEOUS INFILTRATION COMPARED TO ORAL MELOXICAM IN HEALTHY ADULT SUBJECTS | $172,335 | 0 | 2 |
| WOUND INFILTRATION WITH LIPOSOMAL BUPIVACAINE VS. STANDARD WOUND INFILTRATION WITH BUPIVACAINE IN PATIENTS UNDERGOING OPEN GYNECOLOGIC SURGERY ON AN ENHANCED RECOVERY PATHWAY A SINGLE-BLINDED, RANDOMIZED, CONTROLLED STUDY | $170,669 | 0 | 1 |
| BUPIVACAINE LIPOSOMAL INJECTION EXPAREL FOR POSTSURGICAL ANALGESIA IN PATIENTS UNDERGOING LAPAROSCOPIC GASTRIC BYPASS A RANDOMIZED, DOUBLE-BLIND, CONTROLLED TRIAL | $153,150 | 0 | 2 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2021 |
|---|---|---|---|---|
| Unknown Provider | — | — | $2.9M | $0 |
| Dr. Mark Kronenfeld, M.d, M.D | Anesthesiology | Brooklyn, NY | $2.5M | $0 |
| Mark Ian Froimson, Md, MD | Orthopaedic Surgery | Cleveland, OH | $2.2M | $0 |
| Jeffrey Gonzales, Md, MD | Anesthesiology | Aurora, CO | $941,625 | $0 |
| Dr. Jeffrey Gadsden, Md, MD | Anesthesiology | Durham, NC | $899,894 | $0 |
| Dr. Jacob Hutchins, M.d, M.D | Anesthesiology | Minneapolis, MN | $880,204 | $0 |
| Vinod Dasa, M.d, M.D | Orthopaedic Surgery | Kenner, LA | $815,092 | $0 |
| James Mueller, M.d, M.D | Anesthesiology | Dallas, TX | $746,825 | $0 |
| Margaret Holtz, M.d, M.D | Pediatric Anesthesiology | Marietta, GA | $730,089 | $0 |
| Gabriel Mena, M.d, M.D | Anesthesiology | Houston, TX | $661,030 | $0 |
| Dr. Gary Schwartz, M.d, M.D | Pain Medicine | Brooklyn, NY | $605,074 | $0 |
| Valentine Gibson | Anesthesiology | Richardson, TX | $600,481 | $0 |
| Dr. Richard Teames, Md, MD | Student in an Organized Health Care Education/Training Program | Fort Worth, TX | $566,108 | $0 |
| Loran Soliman, M.d, M.D | Anesthesiology | Charlotte, NC | $543,752 | $0 |
| Dr. Nirav Amin, M.d, M.D | Orthopaedic Surgery | Placentia, CA | $458,367 | $0 |
| Karina Gritsenko | Anesthesiology | Bronx, NY | $455,028 | $0 |
| Dr. Daniel Fenton, Dmd, DMD | Dentist | Port St Lucie, FL | $446,593 | $0 |
| Christopher Varacallo, D.o, D.O | Sports Medicine | Du Bois, PA | $443,395 | $0 |
| Joshua Urban, M.d, M.D | Orthopaedic Surgery | Omaha, NE | $415,244 | $0 |
| Dr. David St Peter, Md, MD | Family Medicine | Saratoga Springs, NY | $394,673 | $0 |
| Sabry Ayad, M.d, M.D | Anesthesiology | Cleveland, OH | $383,935 | $0 |
| Aaron Berg, D.o, D.O | Anesthesiology | Minneapolis, MN | $359,873 | $0 |
| Gerald Maccioli, Md, MD | Anesthesiology | Raleigh, NC | $329,678 | $0 |
| Darin Rentz | Anesthesiology | Lakewood, CO | $311,199 | $0 |
| William Rogenmoser, D.o, D.O | Physical Medicine & Rehabilitation | Alexandria, LA | $307,348 | $0 |
Ad
Top Products
- EXPAREL $46.1M
- Exparel $12.8M
Associated Products (5)
- EXPAREL $48.4M
- Exparel $12.8M
- Iovera $4.2M
- IOVERA SYSTEM $1.0M
- Iovera System $424,854
Payment Categories
- Food & Beverage $3.1M
- Consulting $11.6M
- Travel & Lodging $3.9M
- Research $27.0M
- Royalties $1,600
About Pacira Pharmaceuticals Incorporated
Pacira Pharmaceuticals Incorporated has made $67.3M in payments to 42,718 healthcare providers, recorded across 99,831 transactions in the CMS Open Payments database. In 2024, the company paid $5.4M. The top product by payment volume is EXPAREL ($46.1M).
Payments were distributed across 244 medical specialties. The top specialty by payment amount is Anesthesiology ($14.4M to 8,222 doctors).
Payment categories include: Food & Beverage ($3.1M), Consulting ($11.6M), Research ($27.0M), Travel & Lodging ($3.9M), Royalties ($1,600).
Pacira Pharmaceuticals Incorporated is associated with 5 products in the CMS Open Payments database, including EXPAREL, Exparel, and Iovera.